Acquired Immunodeficiency in ANCA Associated Vasculitis — ACQUIVAS  

Systemic Vasculitis Clinical Trial

Official title: Acquired Immunodeficiency in ANCA (Antineutrophil Cytoplasmic Antibody) Associated Vasculitis

Status Not yet recruiting

Clinical Trial Summary

This study will address the following hypothesis: Rituximab therapy leads to an acquired immune deficiency, as demonstrated by impaired vaccine responses, in AAV patients.

Aims:

1. To investigate whether rituximab leads to immune deficiency in patients with AAV when compared to both disease and healthy controls.

2. To investigate whether the degree of immune deficiency is associated with the degree of B cell depletion.

3. To investigate whether T-independent vaccine responses are more severely affected than T-dependent vaccine responses after rituximab and whether a conjugated vaccine will overcome this postulated deficit in T independent vaccine responses.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Immunologic Deficiency Syndromes
• Systemic Vasculitis
• Vasculitis

• NCT number: NCT03514979
• Study type: Interventional
• Source: Cambridge University Hospitals NHS Foundation Trust
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: June 2018
• Completion date: January 2021